DPP-4 inhibitor for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
CORONADO NCT04324736		OBS	DPP-4 inhibitor	control	COVID 19 hospitalized	NA	596/1853	inconclusive
COVID 19 all comers meta-analysis
Rhee (National Health Insurance Review and Assessment Service of Korea)		OBS	DPP-4 inhibitor	control	COVID 19 all comers	NA	263/569	suggested	suggested 64 % decrease in death or transfer to ICU
Rhee (National Health Insurance Service database)		OBS	DPP-4 inhibitor	control	COVID 19 all comers	NA	175/529	suggested	suggested 70 % decrease in death or transfer to ICU
COVID-19 severe or critically meta-analysis
Abuhasira NCT04371978		RCT	DPP-4 inhibitor	standard of care	COVID-19 severe or critically	some concern	32/32	inconclusive	inconclusive 70 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID 19 all comers meta-analysis

COVID-19 severe or critically meta-analysis